公开(公告)号：US09611244B2

公开(公告)日：2017-04-04

申请号：US15148210

申请日：2016-05-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro

IPC: C07D317/72 ,  C07C317/12 ,  C07D309/28 ,  C07C317/44 ,  C07C317/46

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like.The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

公开(公告)号：US20190192549A1

公开(公告)日：2019-06-27

申请号：US16185258

申请日：2018-11-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： MASATO YOSHIKAWA ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Yoshitomi ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  A61K47/68 ,  A61K31/7076

CPC classification number: A61K31/7084 ,  A61K31/7076 ,  A61K47/6807 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20210106607A1

公开(公告)日：2021-04-15

申请号：US17065242

申请日：2020-10-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： MASATO YOSHIKAWA ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02 ,  A61K47/68 ,  A61K31/7076

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US09533966B2

公开(公告)日：2017-01-03

申请号：US15175292

申请日：2016-06-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro

IPC: C07D317/72

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

Abstract translation: （其中，在说明书中更详细地说明每个符号）。

公开(公告)号：US10807987B2

公开(公告)日：2020-10-20

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US12171777B2

公开(公告)日：2024-12-24

申请号：US18310467

申请日：2023-05-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61K31/7076 ,  A61K47/68 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US11702419B2

公开(公告)日：2023-07-18

申请号：US17201878

申请日：2021-03-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

CPC classification number: C07D487/04 ,  A61K9/2095 ,  A61K9/4833 ,  A61P25/00 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US11666594B2

公开(公告)日：2023-06-06

申请号：US17065242

申请日：2020-10-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02 ,  A61K47/68 ,  A61K31/7076

CPC classification number: A61K31/7084 ,  A61K31/7076 ,  A61K47/6807 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US10738004B2

公开(公告)日：2020-08-11

申请号：US16331962

申请日：2017-09-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Nobuyuki Negoro ,  Masashi Yamasaki ,  Takahiro Tanaka ,  Naomi Kitamoto

IPC: C07C317/46 ,  A61K31/235 ,  A61P1/16 ,  A61P9/10 ,  A61P37/02 ,  A61P29/00 ,  A61P25/02 ,  A61P43/00

Abstract: Provided is a compound, such as ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl) -3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof, having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI).

公开(公告)号：US09828357B2

公开(公告)日：2017-11-28

申请号：US15356906

申请日：2016-11-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro ,  Taisuke Katoh ,  Masashi Yamasaki ,  Takahiro Tanaka ,  Naomi Kitamoto

IPC: C07D317/72 ,  C07C317/12 ,  C07D309/28 ,  C07C317/44 ,  C07C317/46

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.